1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
- MORE
About Peanut Allergy
Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. The analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the peanut allergy market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of peanut allergy across the globe.
The market is divided into the following segments based on geography:
Key vendor
Peanut allergy is one of the most common types of food allergies that results in itchiness, abdominal pain, swelling, sneezing, diarrhea, and cardiac arrest. The analysts forecast the Global Peanut Allergy Market to grow at a CAGR of 89.68% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the peanut allergy market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of peanut allergy across the globe.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Key vendor
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
- Increase in collaborations for R&D
- For a full, detailed list, view the full report
- Avoiding the consumption of peanuts
- For a full, detailed list, view the full report
- Business strategy framework in form of spin-offs
- For a full, detailed list, view the full report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
PART 13: VENDOR LANDSCAPE
List of Exhibits
Exhibit 01: Global food allergy market
Exhibit 02: Segments of global food allergy market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global peanut allergy market pipeline: Overview
Exhibit 18: Peanut allergy market pipeline: Overview
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Peanut protein - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Peanut protein - Year-over-year growth 2019-2023 (%)
Exhibit 23: Vaccine - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Vaccine - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Molecules in late-stage development
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Spin-off companies and their funding agencies
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Aimmune Therapeutics - Vendor overview
Exhibit 48: Aimmune Therapeutics - Business segments
Exhibit 49: Aimmune Therapeutics - Organizational developments
Exhibit 50: Aimmune Therapeutics - Segment focus
Exhibit 51: Aimmune Therapeutics - Key offerings
Exhibit 52: Aimmune Therapeutics - Key customers
Exhibit 53: Aravax - Vendor overview
Exhibit 54: Aravax - Business segments
Exhibit 55: Aravax - Organizational developments
Exhibit 56: Aravax - Segment focus
Exhibit 57: Aravax - Key offerings
Exhibit 58: Aravax - Key customers
Exhibit 59: DBV Technologies - Vendor overview
Exhibit 60: DBV Technologies - Business segments
Exhibit 61: DBV Technologies - Organizational developments
Exhibit 62: DBV Technologies - Geographic focus
Exhibit 63: DBV Technologies - Segment focus
Exhibit 64: DBV Technologies - Key offerings
Exhibit 65: DBV Technologies - Key customers
Exhibit 66: HAL Allergy - Vendor overview
Exhibit 67: HAL Allergy - Business segments
Exhibit 68: HAL Allergy - Organizational developments
Exhibit 69: HAL Allergy - Key offerings
Exhibit 70: HAL Allergy - Key customers
Exhibit 71: Immunomic Therapeutics - Vendor overview
Exhibit 72: Immunomic Therapeutics - Business segments
Exhibit 73: Immunomic Therapeutics - Organizational developments
Exhibit 74: Immunomic Therapeutics - Key offerings
Exhibit 75: Immunomic Therapeutics - Key customers
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Peanut protein - Market size and forecast 2018-2023
- Vaccine - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
- Research methodology
- List of abbreviations
List of Exhibits
Exhibit 01: Global food allergy market
Exhibit 02: Segments of global food allergy market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global peanut allergy market pipeline: Overview
Exhibit 18: Peanut allergy market pipeline: Overview
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Peanut protein - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Peanut protein - Year-over-year growth 2019-2023 (%)
Exhibit 23: Vaccine - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Vaccine - Year-over-year growth 2019-2023 (%)
Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 33: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Molecules in late-stage development
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Spin-off companies and their funding agencies
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Aimmune Therapeutics - Vendor overview
Exhibit 48: Aimmune Therapeutics - Business segments
Exhibit 49: Aimmune Therapeutics - Organizational developments
Exhibit 50: Aimmune Therapeutics - Segment focus
Exhibit 51: Aimmune Therapeutics - Key offerings
Exhibit 52: Aimmune Therapeutics - Key customers
Exhibit 53: Aravax - Vendor overview
Exhibit 54: Aravax - Business segments
Exhibit 55: Aravax - Organizational developments
Exhibit 56: Aravax - Segment focus
Exhibit 57: Aravax - Key offerings
Exhibit 58: Aravax - Key customers
Exhibit 59: DBV Technologies - Vendor overview
Exhibit 60: DBV Technologies - Business segments
Exhibit 61: DBV Technologies - Organizational developments
Exhibit 62: DBV Technologies - Geographic focus
Exhibit 63: DBV Technologies - Segment focus
Exhibit 64: DBV Technologies - Key offerings
Exhibit 65: DBV Technologies - Key customers
Exhibit 66: HAL Allergy - Vendor overview
Exhibit 67: HAL Allergy - Business segments
Exhibit 68: HAL Allergy - Organizational developments
Exhibit 69: HAL Allergy - Key offerings
Exhibit 70: HAL Allergy - Key customers
Exhibit 71: Immunomic Therapeutics - Vendor overview
Exhibit 72: Immunomic Therapeutics - Business segments
Exhibit 73: Immunomic Therapeutics - Organizational developments
Exhibit 74: Immunomic Therapeutics - Key offerings
Exhibit 75: Immunomic Therapeutics - Key customers
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
- MORE
Global Peanut Allergy Market 2019-2023
The author of the report recognizes the following company as the key player in the global peanut allergy market: Aimmune Therapeutics, Aravax, DBV Technologies, HAL Allergy, and Immunomic Therapeutics.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the business strategy framework in form of spin-offs. Spin-offs are done by companies to increase the focus on emerging businesses or for technologies that have the potential to disrupt the market. Universities and research institutes are also following this strategy to develop novel therapies to treat various indications.”
According to the report, one driver influencing this market is the driven by the increase in collaborations for R&D. Drug development and marketing is an expensive and lengthy affair in the pharmaceutical industry as the peanut allergy therapy companies need extensive funding, advanced manufacturing units, and a strong distribution network. Several peanut allergy therapy companies are engaging in collaborations to gain a strong foothold on funds and skill set to develop novel peanut allergy treatment methods.
Further, the report states that one challenge affecting this market is avoiding the consumption of peanuts. The occurrence of peanut allergy is one of the rapidly increasing allergies in developed countries and is usually life-long once acquired, and the avoidance of consumption of peanuts is expected to hamper the market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following company as the key player in the global peanut allergy market: Aimmune Therapeutics, Aravax, DBV Technologies, HAL Allergy, and Immunomic Therapeutics.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the business strategy framework in form of spin-offs. Spin-offs are done by companies to increase the focus on emerging businesses or for technologies that have the potential to disrupt the market. Universities and research institutes are also following this strategy to develop novel therapies to treat various indications.”
According to the report, one driver influencing this market is the driven by the increase in collaborations for R&D. Drug development and marketing is an expensive and lengthy affair in the pharmaceutical industry as the peanut allergy therapy companies need extensive funding, advanced manufacturing units, and a strong distribution network. Several peanut allergy therapy companies are engaging in collaborations to gain a strong foothold on funds and skill set to develop novel peanut allergy treatment methods.
Further, the report states that one challenge affecting this market is avoiding the consumption of peanuts. The occurrence of peanut allergy is one of the rapidly increasing allergies in developed countries and is usually life-long once acquired, and the avoidance of consumption of peanuts is expected to hamper the market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
Note: Product cover images may vary from those shown
